No Data
Leerink Partners Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $48
Express News | Uniqure NV : Leerink Partners Raises Target Price to $48 From $44
Gene Therapy Developers Rise on Comments From FDA's Makary
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $70 Price Target
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Sector Update: Health Care Stocks Decline Late Afternoon